Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
Sometimes we come across an article we wish we had read earlier. This was the case with the publication by Zhao and colleagues[1]. The article, now more than 12 years old, was written in the ‘early’ days of biological drug Continue reading PK/PD of BIOLOGICALS
Thrombotic thrombocytopenic purpura (TTP) is a devastating disease with a downhill course of neurologic, renal and cardiac complications leading to death at a young age if untreated. Thrombocytopenia and thrombosis are its hallmark, with fever, anemia and neurologic deficits. It Continue reading NANOBODIES FOR AUTOIMMUNE DISEASES
Today we discuss the group of BAFF/APRIL inhibitors, specifically the three TACI mAb constructs that are currently in development. They were tested in a broad gamut of B-cell indications but failed to show efficacy in many. So far, consistent clinical Continue reading BAFF / APRIL Inhibitors Homing in on IgAN
With the average number of 6-7 authors per (clinical) publication and an increasing trend for multi-authored articles there are now plenty of opportunities for industrious clinicians to publish. Here are just a few examples of super-achievers from the Infectious Disease Continue reading PUBLICATION OVERACHIEVERS
GSK’s pipeline in anti-infectives is impressive. It comprises drugs for bacterial, mycobacterial, fungal, viral infections, and for malaria; in addition, they have a number of vaccines in development. Several antibiotics are listed on their website targeting UTI pathogens, and one Continue reading BLUJEPA / Gepotidacin APPROVED FOR UNCOMPLICATED UTI – 1